Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Replimune Group Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Black Diamond Therapeutics Inc. June 26, 202638.3%
-
Replimune Group Inc. September 2, 202584.4%
-
Black Diamond Therapeutics Inc. May 16, 202375.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 2, 2026 | Replimune Group Inc. | Option exercise | +43,169 | $1.75 | $75,546 |
| Nov 2, 2026 | Replimune Group Inc. | Open-market sale | −21,500 | $19.00 | $408,500 |
| Dec 9, 2025 | Replimune Group Inc. | Option exercise | +3,169 | $1.75 | $5,546 |
| Dec 9, 2025 | Replimune Group Inc. | Open-market sale | −3,169 | $10.40 | $32,958 |
Questions about Kapil Dhingra
What boards is Kapil Dhingra on?
Kapil Dhingra sits on the boards of Black Diamond Therapeutics Inc. and Replimune Group Inc.
How long has Kapil Dhingra served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.